Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07090746
Active, not recruiting Not applicable

Evaluation of Dentoalveolar Changes of Clear Aligners Versus Fixed Orthodontic Appliances on Skeletal Class I Non-extraction Patients With Dental Crowding

NCT07090746 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2023-12-30
Last updated
2026-01-27

Condition(s) studied

Skeletal Class I Non-extraction Patients With Dental Crowding

Investigational drug(s) / intervention(s)

Clear alignerFixed orthodontic appliance

Clear aligner: Clear aligner

Fixed orthodontic appliance: Fixed orthodontic appliance

Study summary

To evaluate dentoalveolar changes of clear aligners versus fixed orthodontic appliances on skeletal class I non-extraction patients with dental crowding.

Eligibility

Sex
ALL
Min age
18 Years
Max age
22 Years
Healthy volunteers
No
Inclusion Criteria: * Complete permanent dentition. * Angle Class I malocclusion cases with mild to moderate crowding (2-6 mm) that can be resolved by dental expansion and interproximal reduction (IPR). * Good oral hygiene. Exclusion Criteria: * Bad oral hygiene. * Previous orthodontic treatment. * Periodontal disease and previous periodontal surgery procedures. * Systemic diseases and/or craniofacial syndromes.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of dentistry mansoura university Al Mansurah Egypt

More Mansoura University trials in Egypt

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07090746 on ClinicalTrials.gov ↗ ← All trials in Egypt